 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | PB103 / Chongqing Precision Biotech
Trial primary completion date, Combination therapy: Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients (clinicaltrials.gov) - Nov 18, 2023
P1/2, N=24, Recruiting, Sponsor: Precision Biotech Taiwan Corp.
Trial primary completion date: Jun 2022 --> Dec 2024
- || PB103 / Chongqing Precision Biotech
Enrollment open, Combination therapy: Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients (clinicaltrials.gov) - Aug 25, 2021
P1/2, N=24, Recruiting, Sponsor: Precision Biotech Taiwan Corp.
Trial primary completion date: Jun 2022 --> Dec 2024 Active, not recruiting --> Recruiting
- | PB103 / Chongqing Precision Biotech
Enrollment closed, Combination therapy: Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients (clinicaltrials.gov) - Mar 9, 2021
P1/2, N=24, Active, not recruiting, Sponsor: Precision Biotech Taiwan Corp.
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- | PB103 / Chongqing Precision Biotech
New P1/2 trial, Combination therapy: Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients (clinicaltrials.gov) - Nov 3, 2020
P1/2, N=24, Recruiting, Sponsor: Precision Biotech Taiwan Corp.